ReviewDrug safety2016
Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.
Review in Drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 29 citations in OpenAlex.
- Familial Short QT Syndrome: Phenotypic Variability and Challenges in Risk Stratification.Journal of clinical medicine · 2026Article
- A Characteristic Electrocardiographic Manifestation Suggests Hypercalcemia.Diagnostics (Basel, Switzerland) · 2025Article
- Effect of chemotherapy and different chemotherapeutic regimens on electrocardiographic parameters in breast cancer women: a retrospective and within-subject longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.Clinical and translational science · 2021Article
- Antiepileptic rufinamide and QTc interval shortening in a patient with long QT syndrome: case report.European heart journal. Case reports · 2020Article
- Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation.Journal of clinical medicine · 2020Review
- Transgenic Rabbit Models in Proarrhythmia Research.Frontiers in pharmacology · 2020Review
- QT Assessment in Early Drug Development: The Long and the Short of It.International journal of molecular sciences · 2019Review
- Therapeutic effects of a taurine-magnesium coordination compound on experimental models of type 2 short QT syndrome.Acta pharmacologica Sinica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The review discusses safety implications of drugs found to shorten the QT/QTc interval. It uses parallels with drug-induced QT/QTc prolongation. It summarizes the evidence that increases in repolarization heterogeneity are likely more important for arrhythmia induction and maintenance than the absolute changes in the QT/QTc duration. The review further compares the direct evidence of proarrhythmia caused by QT-prolonging and -shortening drugs. At present, there is little proof of QT-shortening drugs causing ventricular fibrillation in more than rare isolated instances. Comparisons of the incidence of the congenital syndromes show that short QT syndrome is much rarer than long QT syndrome, similar to the findings of short QT intervals compared with long QT intervals in the general population. Nevertheless, potential concerns come from experimental drugs developed to increase the current of potassium-rectifying channels. Some of these drugs were found to cause ventricular fibrillation in isolated hearts. Still, population exposure to drug-induced QT shortening is likely substantially lower compared with QT prolongation, especially if considering that most of the processes that decrease the so-called repolarization reserve are associated with QT prolongation. Finally, the review lists reasons why purely theoretical concepts of pharmaceutical risk cannot be used to develop regulatory guidance and concludes that at present, no additional tests and/or general acceptance restrictions are needed for the approval of QT-shortening drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.